Crucial role of androgen receptor in vascular H2S biosynthesis induced by testosterone

British Journal of Pharmacology

Volumn 172, Issue 6, 2015, Pages 1505-1515

  Brancaleone, V ^a,b   Vellecco, V ^b   Matassa, D S ^b   D'Emmanuele Di Villa Bianca, R ^b   Sorrentino, Raffaella ^b   Ianaro, A ^b   Bucci, M ^b   Esposito, F ^b   Cirino, G ^b  

^a UNIVERSITY OF BASILICATA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

androgen receptor; heat shock protein 90; hydrogen sulphide; testosterone; vascular function

Indexed keywords

ANDROGEN RECEPTOR; CYSTATHIONINE GAMMA LYASE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HYDROGEN SULFIDE; NILUTAMIDE; PROPARGYLGLYCINE; TESTOSTERONE; ALKYNE; ANTIANDROGEN; GLYCINE; IMIDAZOLIDINE DERIVATIVE; VASODILATOR AGENT;

ADULT; ANIMAL TISSUE; ARTICLE; BIOSYNTHESIS; BLOOD LEVEL; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HORMONE ACTION; HUMAN; HYDROGEN SULFIDE BLOOD LEVEL; IMMUNOPRECIPITATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN QUATERNARY STRUCTURE; RAT; SEX DIFFERENCE; SURFACE PLASMON RESONANCE; VASODILATATION; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; METABOLISM; MIDDLE AGED; THORACIC AORTA; WISTAR RAT;

ADULT; ALKYNES; ANDROGEN ANTAGONISTS; ANIMALS; AORTA, THORACIC; FEMALE; GLYCINE; HUMANS; HYDROGEN SULFIDE; IMIDAZOLIDINES; MALE; MIDDLE AGED; RATS; RATS, WISTAR; RECEPTORS, ANDROGEN; SEX FACTORS; TESTOSTERONE; VASODILATION; VASODILATOR AGENTS;

EID: 84923649380     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12740     Document Type: Article

References (63)

1. Adams MR, Williams JK, Kaplan JR, (1995). Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. Arterioscler Thromb Vasc Biol 15: 562-570.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear hormone receptors. Br J Pharmacol 170: 1652-1675.
3. Arnal JF, Fontaine C, Billon-Gales A, Favre J, Laurell H, Lenfant F, et al. (2010). Estrogen receptors and endothelium. Arterioscler Thromb Vasc Biol 30: 1506-1512.
4. Asimakopoulou A, Panopoulos P, Chasapis CT, Coletta C, Zhou Z, Cirino G, et al. (2013). Selectivity of commonly used pharmacological inhibitors for cystathionine beta synthase (CBS) and cystathionine gamma lyase (CSE). Br J Pharmacol 169: 922-932.
5. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, et al. (1996). The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 335: 1-7.
6. Boada LD, Fernandez L, Zumbado M, Luzardo OP, Chirino R, Diaz-Chico BN, (1996). Identification of a specific binding site for the anabolic steroid stanozolol in male rat liver microsomes. J Pharmacol Exp Ther 279: 1123-1129.
7. Bucci M, Roviezzo F, Cicala C, Pinto A, Cirino G, (2002). 17-beta-oestradiol-induced vasorelaxation in vitro is mediated by eNOS through hsp90 and akt/pkb dependent mechanism. Br J Pharmacol 135: 1695-1700.
8. Bucci M, Mirone V, Di Lorenzo A, Vellecco V, Roviezzo F, Brancaleone V, et al. (2009). Hydrogen sulphide is involved in testosterone vascular effect. Eur Urol 56: 378-383.
9. Campelo AE, Cutini PH, Massheimer VL, (2012). Cellular actions of testosterone in vascular cells: mechanism independent of aromatization to estradiol. Steroids 77: 1033-1040.
10. Crews JK, Khalil RA, (1999). Antagonistic effects of 17 beta-estradiol, progesterone, and testosterone on Ca2+ entry mechanisms of coronary vasoconstriction. Arterioscler Thromb Vasc Biol 19: 1034-1040.
11. Cutini P, Selles J, Massheimer V, (2009). Cross-talk between rapid and long term effects of progesterone on vascular tissue. J Steroid Biochem Mol Biol 115: 36-43.
12. Dal Piaz F, Tosco A, Eletto D, Piccinelli AL, Moltedo O, Franceschelli S, et al. (2010). The identification of a novel natural activator of p300 histone acetyltranferase provides new insights into the modulation mechanism of this enzyme. Chembiochem 11: 818-827.
13. Deenadayalu V, Puttabyatappa Y, Liu AT, Stallone JN, White RE, (2012). Testosterone-induced relaxation of coronary arteries: activation of BKCa channels via the cGMP-dependent protein kinase. Am J Physiol Heart Circ Physiol 302: H115-H123.
14. Deenadayalu VP, White RE, Stallone JN, Gao X, Garcia AJ, (2001). Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol Heart Circ Physiol 281: H1720-H1727.
15. Defranco DB, (2000). Role of molecular chaperones in subnuclear trafficking of glucocorticoid receptors. Kidney Int 57: 1241-1249.
16. Ettinger B, Friedman GD, Bush T, Quesenberry CP Jr, (1996). Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 87: 6-12.
17. Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M, (2000). Multiple actions of steroid hormones-a focus on rapid, nongenomic effects. Pharmacol Rev 52: 513-556.
18. Farish E, Spowart K, Barnes JF, Fletcher CD, Calder A, Brown A, et al. (1996). Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein(a) and LDL subfractions. Atherosclerosis 126: 77-84.
19. Fernandez L, Chirino R, Boada LD, Navarro D, Cabrera N, del Rio I, et al. (1994). Stanozolol and danazol, unlike natural androgens, interact with the low affinity glucocorticoid-binding sites from male rat liver microsomes. Endocrinology 134: 1401-1408.
20. Fusco F, di Villa Bianca R, Mitidieri E, Cirino G, Sorrentino R, Mirone V, (2012). Sildenafil effect on the human bladder involves the L-cysteine/hydrogen sulfide pathway: a novel mechanism of action of phosphodiesterase type 5 inhibitors. Eur Urol 62: 1174-1180.
21. Gallo MA, Kaufman D, (1997). Antagonistic and agonistic effects of tamoxifen: significance in human cancer. Semin Oncol 24 (1 Suppl. 1): S1-71-S1-80.
22. Garcia-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetropoulos A, et al. (1998). Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 392: 821-824.
23. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, et al. (2000). Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 87: 677-682.
24. Herman SM, Robinson JT, McCredie RJ, Adams MR, Boyer MJ, Celermajer DS, (1997). Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men. Arterioscler Thromb Vasc Biol 17: 2004-2009.
25. Hu JC, Williams SB, O'Malley AJ, Smith MR, Nguyen PL, Keating NL, (2012). Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol 61: 1119-1128.
26. Huang M, Li J, Teoh H, Man RY, (1999). Low concentrations of 17beta-estradiol reduce oxidative modification of low-density lipoproteins in the presence of vitamin C and vitamin E. Free Radic Biol Med 27: 438-441.
27. Ishigami M, Hiraki K, Umemura K, Ogasawara Y, Ishii K, Kimura H, (2009). A source of hydrogen sulfide and a mechanism of its release in the brain. Antioxid Redox Signal 11: 205-214.
28. Ishii I, Akahoshi N, Yamada H, Nakano S, Izumi T, Suematsu M, (2010). Cystathionine gamma-lyase-deficient mice require dietary cysteine to protect against acute lethal myopathy and oxidative injury. J Biol Chem 285: 26358-26368.
29. Jockenhovel F, Bullmann C, Schubert M, Vogel E, Reinhardt W, Reinwein D, et al. (1999). Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism 48: 590-596.
30. Keaney JF Jr, Shwaery GT, Xu A, Nicolosi RJ, Loscalzo J, Foxall TL, et al. (1994). 17 beta-estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. Circulation 89: 2251-2259.
31. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
32. Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P, (1987). Functional domains of the human estrogen receptor. Cell 51: 941-951.
33. Leung SW, Teoh H, Keung W, Man RY, (2007). Non-genomic vascular actions of female sex hormones: physiological implications and signalling pathways. Clin Exp Pharmacol Physiol 34: 822-826.
34. Levonen AL, Lapatto R, Saksela M, Raivio KO, (2000). Human cystathionine gamma-lyase: developmental and in vitro expression of two isoforms. Biochem J 347 (Pt 1): 291-295.
35. Levy D, Kannel WB, (1988). Cardiovascular risks: new insights from Framingham. Am Heart J 116 (1 Pt 2): 266-272.
36. Liu PY, Death AK, Handelsman DJ, (2003). Androgens and cardiovascular disease. Endocr Rev 24: 313-340.
37. Lu Y, O'Dowd BF, Orrego H, Israel Y, (1992). Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase. Biochem Biophys Res Commun 189: 749-758.
38. Lu Y, Fu Y, Ge Y, Juncos LA, Reckelhoff JF, Liu R, (2012). The vasodilatory effect of testosterone on renal afferent arterioles. Gend Med 9: 103-111.
39. Malkin CJ, Jones RD, Jones TH, Channer KS, (2006). Effect of testosterone on ex vivo vascular reactivity in man. Clin Sci (Lond) 111: 265-274.
40. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
41. Mooradian AD, Morley JE, Korenman SG, (1987). Biological actions of androgens. Endocr Rev 8: 1-28.
42. Nettleship JE, Jones RD, Channer KS, Jones TH, (2009). Testosterone and coronary artery disease. Front Horm Res 37: 91-107.
43. Papierska L, Rabijewski M, Kasperlik-Zaluska A, Zgliczynski W, (2012). Effect of DHEA supplementation on serum IGF-1, osteocalcin, and bone mineral density in postmenopausal, glucocorticoid-treated women. Adv Med Sci 57: 51-57.
44. Perusquia M, Navarrete E, Gonzalez L, Villalon CM, (2007). The modulatory role of androgens and progestins in the induction of vasorelaxation in human umbilical artery. Life Sci 81: 993-1002.
45. Pratt WB, Toft DO, (1997). Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18: 306-360.
46. Puttabyatappa Y, Stallone JN, Ergul A, El-Remessy AB, Kumar S, Black S, et al. (2013). Peroxynitrite mediates testosterone-induced vasodilation of microvascular resistance vessels. J Pharmacol Exp Ther 345: 7-14.
47. Reckelhoff JF, Zhang H, Granger JP, (1998). Testosterone exacerbates hypertension and reduces pressure-natriuresis in male spontaneously hypertensive rats. Hypertension 31 (1 Pt 2): 435-439.
48. Saartok T, Dahlberg E, Gustafsson JA, (1984). Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin. Endocrinology 114: 2100-2106.
49. Schubert M, Bullmann C, Minnemann T, Reiners C, Krone W, Jockenhovel F, (2003). Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm Res 60: 21-28.
50. Shibuya N, Mikami Y, Kimura Y, Nagahara N, Kimura H, (2009). Vascular endothelium expresses 3-mercaptopyruvate sulfurtransferase and produces hydrogen sulfide. J Biochem 146: 623-626.
51. Smith AM, Bennett RT, Jones TH, Cowen ME, Channer KS, Jones RD, (2008). Characterization of the vasodilatory action of testosterone in the human pulmonary circulation. Vasc Health Risk Manag 4: 1459-1466.
52. Soisson V, Brailly-Tabard S, Empana JP, Feart C, Ryan J, Bertrand M, et al. (2012). Low plasma testosterone and elevated carotid intima-media thickness: importance of low-grade inflammation in elderly men. Atherosclerosis 223: 244-249.
53. Southren AL, Tochimoto S, Carmody NC, Isurugi K, (1965). Plasma production rates of testosterone in normal adult men and women and in patients with the syndrome of feminizing testes. J Clin Endocrinol Metab 25: 1441-1450.
54. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. (1991). Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 325: 756-762.
55. Stipanuk MH, (2004). Sulfur amino acid metabolism: pathways for production and removal of homocysteine and cysteine. Annu Rev Nutr 24: 539-577.
56. Stipanuk MH, Beck PW, (1982). Characterization of the enzymic capacity for cysteine desulphhydration in liver and kidney of the rat. Biochem J 206: 267-277.
57. Tep-areenan P, Kendall DA, Randall MD, (2002). Testosterone-induced vasorelaxation in the rat mesenteric arterial bed is mediated predominantly via potassium channels. Br J Pharmacol 135: 735-740.
58. Traish AM, Guay A, Feeley R, Saad F, (2009). The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 30: 10-22.
59. Workman P, Burrows F, Neckers L, Rosen N, (2007). Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 1113: 202-216.
60. Wu FC, von Eckardstein A, (2003). Androgens and coronary artery disease. Endocr Rev 24: 183-217.
61. Yang G, Wu L, Jiang B, Yang W, Qi J, Cao K, et al. (2008). H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science 322: 587-590.
62. Zanardo RC, Brancaleone V, Distrutti E, Fiorucci S, Cirino G, Wallace JL, (2006). Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J 20: 2118-2120.
63. Zhao X, Zhang LK, Zhang CY, Zeng XJ, Yan H, Jin HF, et al. (2008). Regulatory effect of hydrogen sulfide on vascular collagen content in spontaneously hypertensive rats. Hypertens Res 31: 1619-1630.